UK lands £500M in biopharma pledges; Teva to shutter New Jersey site
Plus, news about Esteve and Regeneron. UK pulls in £500M investment: As part of the UK’s Autumn budget, Vertex Pharmaceuticals said it will invest over £300 million in a new R&D site in Oxford, UK ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.